Status:
COMPLETED
Effect of Tetrabenazine on Stroop Interference in HD
Lead Sponsor:
New York Medical College
Conditions:
Huntington Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Tetrabenazine has been shown to improve gating of abnormal visual stimuli and improve postural stability in Huntington disease (HD) patients as measured by computerized dynamic posturography testing. ...
Eligibility Criteria
Inclusion
- Established diagnosis of Huntington disease by movement disorders expert
- Patients currently taking tetrabenazine.
- Patients should not have taken dopamine receptor blocking medication for at least three days
Exclusion
- \-
Key Trial Info
Start Date :
March 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2018
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT01834911
Start Date
March 1 2013
End Date
January 1 2018
Last Update
May 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Terence Cardinal Cooke Health Care Center
New York, New York, United States, 10029